# Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

> **NCT00425321** · PHASE2 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 259 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** RWJ-445380 100 mg
- **DRUG:** RWJ-445380 200 mg
- **DRUG:** RWJ-445380 300 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00425321
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 259 (ACTUAL)
- **Last updated:** 2014-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00425321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00425321, "Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00425321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*